The 19 linked references in paper A. Mudunov M., А. Мудунов М. (2017) “НИВОЛУМАБ В ЛЕЧЕНИИ РЕФРАКТЕРНОГО РЕЦИДИВНОГО И МЕТАСТАТИЧЕСКОГО ПЛОСКОКЛЕТОЧНОГО РАКА ОРГАНОВ ГОЛОВЫ И ШЕИ. РЕЗУЛЬТАТЫ КЛИНИЧЕСКОГО ИССЛЕДОВАНИЯ III ФАЗЫ CHECKMATE 141 // NIVOLUMAB IN THE TREATMENT OF REFRACTORY RECURRENT AND METАSTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. THE RESULTS OF A PHASE III CLINICAL TRIAL (CHECKMATE 141)” / spz:neicon:ogsh:y:2017:i:3:p:74-86

  1. 09;92:4–14. DOI: 10.1016/j. radonc.2009.04.014. PMID: 19446902. 2. Bernier J., Domenge C., Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350(19):1945–52. DOI: 10.1056/NEJMoa032641. PMID: 15128894.
  2. Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44. DOI: 10.1056/ NEJMoa032646. PMID: 15128893.
  3. Saloura V., Cohen E.E., Licitra L. et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2014;73:1227–39. DOI: 10.1007/s00280-014-2459-z. PMID: 24714973.
  4. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–61. DOI: 10.1016/j.ccell.2015.03.001. PMID: 25858804.
  5. Li J., Jie H.B., Lei Y. et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015;75:508–18. DOI: 10.1158/00085472.CAN-14-1215. PMID: 25480946.
  6. Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128–38. DOI: 10.1158/0008-5472.CAN-12-2606. PMID: 23135914.
  7. Concha-Benavente F., Srivastava R.M., Trivedi S. et al. Identification of the cellintrinsic and -extrinsic pathways downstream of EGFR and IFNγ that inducePD-L1 expression in head and neck cancer. Cancer Res 2016;76:1031–43. DOI: 10.1158/0008-5472.CAN-15-2001. PMID: 26676749.
  8. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–51. DOI: 10.1200/ jco.2004.10.041.
  9. Muenst S., Läubli H., Soysal S.D. et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 2016; 279(6):541–62. DOI: 10.1111/joim.12470. PMID: 26748421.
  10. Gillison M.L. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009;21:439–44. DOI: 10.1097/ CCO.0b013e32832f3e1b.
  11. Ferris R.L. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015;33:3293–304. DOI: 10.1200/jco.2015.61.1509.
  12. Kuss I., Hathaway B., Ferris R.L., Gooding W., Whiteside T.L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:3755–62. DOI: 10.1158/1078–0432.ccr-04-0054.
  13. Nguyen N., Bellile E., Thomas D. et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. HeadNeck 2016;38(7):1074–84. DOI: 10.1002/ hed.24406. PMID: 26879675.
  14. Lalami Y., Awada A. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev 2016;43:113–23. DOI: 10.1016/j.ctrv.2016.01.001.
  15. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. DOI: 10.1038/ nature10673. PMID: 26827699.
  16. Zandberg D.P., Strome S.E. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627–32. DOI: 10.1016/j. oraloncology.2014.04.003. PMID: 24819861.
  17. 4; 74(24):7205–16. DOI: 10.1158/0008-5472.can-14-1913. 20. Swanson M.S., Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current data. Oral Oncology 2015; 51:12–15. DOI: 10.1016/j.oraloncology.2014.10.010. PMID: 25459157.
  18. Alexandrov L.B., Nik-Zainal S., Wedge D.C. et al. Signatures of mutational processes in human cancer. Nature 2013;500:415–21. DOI: 10.1038. nature12477. PMID: 23945592.
  19. Ferris R.L., Blumenschein G.Jr, Fayette J. et al. Nivolumab for Recurrent SquamousCell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252. PMID: 27718784.